Sentibio: Press Releases

Senti Bio Highlights Colorectal Cancer Preclinical Data from Logic Gated CAR-NK Cell Program at 36th SITC Annual Meeting

11/12/2021

Senti Bio to Present Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting

11/04/2021

Senti Bio CEO Appointed to The Alliance for Regenerative Medicine 2022 Board of Directors

10/21/2021

Senti Bio Awarded Funding from National Cancer Institute (NCI) to Support Development of Logic Gated Allogeneic CAR-NK Cell Therapy SENTI-202 to Treat Acute Myeloid Leukemia

09/28/2021

Senti Bio Adds Prominent Scientific and Industry Leaders to its Scientific Advisory Board

08/17/2021

Senti Bio Signs Lease Agreement and Begins Design of Clinical and Commercial-Scale Manufacturing Facility for Allogeneic CAR-NK Cell Therapies

06/15/2021

Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine

05/26/2021

Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at ISCT Annual Meeting

05/25/2021

Senti Bio Announces Key Leadership Appointments

05/19/2021

Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at ASGCT 24th Annual Meeting

05/11/2021

1
2 (current)
3
4